Show simple item record

dc.contributor.authorTimire, C
dc.contributor.authorTakarinda, KC
dc.contributor.authorHarries, AD
dc.contributor.authorMutunzi, H
dc.contributor.authorManyame-Murwira, B
dc.contributor.authorKumar, AMV
dc.contributor.authorSandy, C
dc.date.accessioned2018-08-08T16:23:12Z
dc.date.available2018-08-08T16:23:12Z
dc.date.issued2018-06-01
dc.date.submitted2018-07-17
dc.identifier.citationHow has the Zimbabwe mycobacterial culture and drug sensitivity testing system among re-treatment tuberculosis patients functioned during the scale-up of the Xpert MTB/RIF assay? 2018, 112 (6):285-293 Trans. R. Soc. Trop. Med. Hyg.en
dc.identifier.issn1878-3503
dc.identifier.pmid29992299
dc.identifier.doi10.1093/trstmh/try054
dc.identifier.urihttp://hdl.handle.net/10144/619255
dc.description.abstractIn Zimbabwe, while the Xpert MTB/RIF assay is being used for diagnosing tuberculosis and rifampicin-resistance, re-treatment tuberculosis (TB) patients are still expected to have culture and drug sensitivity testing (CDST) performed at national reference laboratories for confirmation. The study aim was to document the Xpert MTB/RIF assay scale-up and assess how the CDST system functioned for re-treatment TB patients.
dc.language.isoenen
dc.publisherOxford University Pressen
dc.rightsPublished by Elsevier Archived on this site with the kind permission of Elsevier Ltd. ([url]http://www.sciencedirect.com/science/journal/00359203[/url]) and the Royal Society of Tropical Medicine and Hygiene ([url]http://www.rstmh.org/transactions.asp[/url])en
dc.titleHow has the Zimbabwe mycobacterial culture and drug sensitivity testing system among re-treatment tuberculosis patients functioned during the scale-up of the Xpert MTB/RIF assay?en
dc.identifier.journalTransactions of the Royal Society of Tropical Medicine and Hygieneen
refterms.dateFOA2019-03-04T14:04:46Z
html.description.abstractIn Zimbabwe, while the Xpert MTB/RIF assay is being used for diagnosing tuberculosis and rifampicin-resistance, re-treatment tuberculosis (TB) patients are still expected to have culture and drug sensitivity testing (CDST) performed at national reference laboratories for confirmation. The study aim was to document the Xpert MTB/RIF assay scale-up and assess how the CDST system functioned for re-treatment TB patients.


Files in this item

Thumbnail
Name:
Timire et al - 2018 - How has ...
Size:
614.1Kb
Format:
PDF

This item appears in the following Collection(s)

Show simple item record